ClinicalTrials.gg
RecruitingNCT04539951ProceedUpdated May 15, 2025

Pragmatic Trial of Obsessive-compulsive Disorder

A Phase 2 interventional study of Sertraline 200 milligram(mg) and Sertraline 300 milligram(mg) in Obsessive-Compulsive Disorder, sponsored by Shanghai Mental Health Center. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-05-15.

Sponsored by Shanghai Mental Health Center · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2020; still recruiting 6 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1,600
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center — 16 open to participants now, 16 under way, none of them phase 3. Obsessive-Compulsive Disorder · Shanghai Mental Health Center.

Planned enrollment
Largest of 25
1,600 · median 60
Started
2020
with 4 others
Phase 2
Only one
of the 28
Primary completion
2027-06
later than 7 of 15 live
Registered
12th of 28
by date

Among the 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, this one has the largest planned enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2020, is the only one in phase 2, reaches primary completion later than 7 of the 15 other live ones, and was the 12th registered.

Obsessive-Compulsive Disorder

637 studies on the registry are indexed under Obsessive-Compulsive Disorder; 167 are open to participants now.

Browse Obsessive-Compulsive Disorder studies →

Open to participants now

16 of the 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center are open now, in 1 country. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 16 open studies →

Where they have run

Who these studies take

Of the 120 Obsessive-Compulsive Disorder studies recruiting now, 30 (25%) set no upper age limit and 82 (68%) stop at 75 or younger; 28 take children under 18; 19 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Obsessive-Compulsive Disorder by Shanghai Mental Health Center, or all of them as a file.
02

Study summary

This study includes a sequenced clinical trial in order to assess the efficacy of several switching or augment strategies when initial treatment is ineffective,and to provide strong evidence for clinical practice and international guidelines for Obsessive-Compulsive Disorder treatments.

Read the detailed description

Selective Serotonin Reuptake Inhibitors(SSRIs) are the first line pharmacotherapy for Obsessive-Compulsive Disorder (OCD) according to APA(American Psychological Association)guideline. Nevertheless, a large proportion (40% or more) of patients response only partially or not at all to treatment with a SSRI. On the basis of the existing sparse literature, several pharmacotherapy options for OCD patients who do not respond, or who respond but do not remit, have been outlined in current treatment guidelines. These include 1) treatment with higher than usual doses of an SSRI, 2) switch to a different SSRI, 3) switch to a different class of medication, 4) augmentation with a dopamine blocker, and 5) augmentation with a glutamatergic agent. There is a need for additional data, particularly real-world data, on how best to choose between these options.

This proposed Randomized Controlled Trial (RCT) study is a multi-center clinical study with a total of 13 centers that specialize in OCD patients. A randomized block design will be used in this study and all eligible participants accepted into this study will undergo an initial course of pharmacotherapy (phase I), and non-remmitters will be randomly allocated to five treatment arms (phase II). In phase I all participants will be treated with sertraline for 12 weeks.In phase II,The 5 arms will comprise 1) treatment with higher than usual doses of sertraline, 2) switch to fluvoxamine, 3) switch to venlafaxine, 4) augmentation with memantine, and 5) augmentation with aripiprazole. Clinicians and patients will know which treatment arm is being employed, but raters will be kept blind to treatment group.

03

Conditions studied

  • Obsessive-Compulsive Disorder

Keywords

  • Obsessive-Compulsive Disorder
  • Pharmacotherapy
  • Treatment-naïve
  • Alternatives
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria:They

  • meet diagnostic criteria for OCD as the primary diagnosis ;
  • are in the age range from 18 to 65 years;
  • have a score of at least 20 on Yale-Brown Obsessive-Compulsive Scale (Y-BOCS);
  • have never received medication for OCD, and have not received any form of psychotherapy for OCD in the past 1 month;
  • have provided written .

exclusion criteria: They

  • have met the DSM-5 diagnostic criteria for Schizophrenia Spectrum and Other Psychotic Disorders, or the Bipolar and Related Disorders;
  • have a moderate or higher risk of suicide (⩾9 on the Suicide Module in the Mini-International Neuropsychiatric Interview (MINI));
  • have substance use that is sufficiently severe to possibly impact negatively on treatment adherence in the past 1 year;
  • have severe depression with Beck Depression Inventory (BDI) score of ≥29;
  • have comorbid psychiatric or medical disorders that may impact negatively on adherence to or on the efficacy of medication (eg borderline personality disorder, CNS disorders);
  • are pregnant or lactating females.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
1,600 participants (estimated)

Study arms

  • Active comparator
    serotonin treatment

    In experimental phase I, all recruited subjects provide written informed consent before any related procedures. Participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks

    Drug: Sertraline 200 milligram(mg)

  • Active comparator
    sequenced treatment alternatives

    If participants in In Experimental phase I do not achieve remission, they will be will be randomly assigned to the second-step treatment (Experimental phase II). The second-step therapy will consist of five treatment options including higher-than-usual-maximal dosage of sertraline, switching to fluvoxamine, switching to venlafaxine, augmentation with memantine, and augmentation with aripiprazole.

    Drug: Sertraline 300 milligram(mg) · Drug: Fluvoxamine · Drug: Venlafaxine · Drug: Augment with Memantine · Drug: Augment with Aripiprazole

Interventions

  • DrugSertraline 200 milligram(mg)

    All included participants will receive sertraline, initially at 50mg/d, with a weekly 50mg/d further increase, to the maximum recommended dosage (200mg/d) or to the maximum tolerated dosage (less than 200mg/d). Patients will be on their maximum dose by week 4, so allowing an assessment of response at 12 weeks

  • DrugSertraline 300 milligram(mg)

    In experimental phase II, the patients in this group will remain on sertraline (higher dosage): where sertraline 200mg has been tolerated, dosage will be increased by 50mg fortnightly to a maximal dose of 300mg/d or to the maximum tolerable dose (less than 300mg/d).

  • Fluvoxamine will be initiated at a dose of 50mg/d, increasing quickly to a maximal dose of 300mg/d or the maximum tolerated dose by week 4.

  • venlafaxine will be initiated at 75mg/d, increasingly weekly by 75mg/day, to a maximal dose of 300 mg/d or the maximum tolerated dose.

  • DrugAugment with Memantine

    Sertraline will be augmented with memantine initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d (10mg twice daily) or the maximum tolerated dose

  • DrugAugment with Aripiprazole

    Sertraline will be augmented with aripiprazole, initially at 5mg/d, and increasing by 5mg/d weekly to a maximal dose of 20mg/d or the maximum tolerated dose

06

What researchers measure

Primary outcomes

  1. Yale-Brown Obsessive-Compulsive Scale (Y-BOCS)

    Y-BOCS is a clinician-rated, 10-item scale, each item rated from 0 (no symptoms) to 4 (extreme symptoms), with separate subtotals for severity of obsessions and compulsions.Patients will be assessed at baseline, week 2, week 4, week 8, week 12, week 16, week 20, month 6.

    Time frame: from baseline to 12 weeks, and 12 weeks to month 6.

Secondary outcomes

  1. The Clinical Global Impression (CGI)

    The Clinical Global Impression (CGI; National Institute of Mental Health) is a clinician-rated scale to assess treatment response in patients with mental disorders. The scale contains three items: Severity of Illness; Global Improvement; Efficacy Index. It requires the clinician to rate how much the patient's illness has improved or worsened relative to a baseline measurement. Patients will be assessed at week 2, week 4, week 8, week 12, week 16, week 20, month 6.

    Time frame: from 2 weeks to 12 weeks, and 12 weeks to month 6.

  2. Beck Anxiety Inventory (BAI)

    BAI is a 21-item inventory which identifies anxiety symptoms and quantifies their intensity. Patients will be assessed at baseline, week 2, week 4, week 8, week 12, week 16, week 20, month 6.

    Time frame: from baseline to 12 weeks, and 12 weeks to month 6.

  3. Beck Depression Inventory(BDI)

    BDI is a 21-item, self-report rating inventory that measures characteristic attitudes and symptoms of depression.Patients will be assessed at baseline, week 2, week 4, week 8, week 12, week 16, week 20, month 6.

    Time frame: from baseline to 12 weeks, and 12 weeks to month 6.

  4. Obsessive-Compulsive Inventory-Revised(OCI-R)

    OCI-R is the measure of election for the assessment of obsessive-compulsive behaviors, given its validity and the short time that its administration requires. Patients will be assessed at baseline, week 2, week 4, week 8, week 12, week 16, week 20, month 6.

    Time frame: from baseline to 12 weeks, and 12 weeks to month 6.

  5. Treatment Emergent Symptom Scale (TESS)

    The Treatment Emergent Symptom Scale (TESS) is used to record side effects. The side effects are assessed on a five-point scale ranging from 0 ("no side effects") to 4 ("severe side effects"). Patients will be assessed at week 2, week 4, week 8, week 12, week 16, week 20, month 6.

    Time frame: from 2 weeks to 12 weeks , and 12 weeks to month 6.

  6. Tolerability scale

    The tolerability of treatment will be defined as side effect discontinuation in this study. as defined by the proportion of patients who discontinued treatment due to adverse events during the study.Patients will be assessed at week 2, week 4, week 8, week 12, week 16, week 20, month 6.

    Time frame: from 2 weeks to 12 weeks , and 12 weeks to month 6.

Other outcomes

  1. Complete Blood Count

    for safety considerations

    Time frame: baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wang P, Gu W, Gao J, Wang C, Fang J, Hu M, Xiang H, Li B, Liu N, Tang W, Wang X, Jia Y, Li Y, Cheng Y, Tang Z, Simpson HB, Stein DJ, Wang Z. Protocol for a Pragmatic Trial of Pharmacotherapy Options Following Unsatisfactory Initial Treatment in OCD (PROCEED). Front Psychiatry. 2022 May 16;13:822976. doi: 10.3389/fpsyt.2022.822976. eCollection 2022. PubMed 35651818 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2020 (actual). Primary completion is estimated for Jun 2027, 81 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2020
First posted
Sep 7, 2020
StartActual
Sep 22, 2020
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2028
Last update
May 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04539951
Collaborators
The first specialized hospital of harbin, Guizhou Provincial People's Hospital, First Affiliated Hospital of Jinan University, West China Hospital, Suzhou Psychiatric Hospital, Nanjing Medical University, Wuhan Mental Health Centre, Seventh People's Hospital of Hangzhou, First Affiliated Hospital of Kunming Medical University, General Hospital of Ningxia Medical University, The First Affiliated Hospital of Nanchang University, The Second Affiliated Hospital of Xinxiang Medical University
Responsible party
Zhen Wang (Chief Psychiatrist, Shanghai Mental Health Center) — Principal investigator
First posted
Sep 7, 2020
Start date
Sep 22, 2020
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 15, 2025

Study contacts

Zhen Wang, PhD,MD
Contact
wangzhen@smhc.org.cn
862134773516
Zhen Wang, PhD,MD
principal investigator · Shanghai Mental Health Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluvoxamine · Venlafaxine

Start the discussion